Drug intelligence / Profile preview

rocbrutinib

Development stage: Phase 3
Lead developer: Lupeng Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Rocbrutinib is a small molecule drug candidate that acts as an inhibitor of Bruton’s tyrosine kinase (BTK). BTK is a key enzyme in the B-cell receptor signaling pathway, which plays a critical role in the proliferation and survival of malignant B cells. By inhibiting BTK, rocbrutinib disrupts B-cell signaling, leading to reduced proliferation and increased apoptosis of cancerous B cells. Rocbrutinib is being developed primarily for the treatment of various B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other related hematologic cancers. The drug is designed to be administered orally.

Brand names: Rocbrutinib
Other names: Rocbrutinib

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on rocbrutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rocbrutinib.

Explore the full profile